DR. MAEN A HUSSEIN M.D. NPI 1356332506

NPI Details

DR. Maen A Hussein, M.D. is a medical oncology internal medicine in Tavares, FL with 30 years of experience. The provider is an internist who specializes in the diagnosis and treatment of all types of cancer and other benign and malignant tumors. This specialist decides on and administers therapy for these malignancies as well as consults with surgeons and radiotherapists on other treatments for cancer. DR. Maen A Hussein, M.D. NPI is 1356332506. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a male.

The provider's business location address is:

4100 WATERMAN WAY
TAVARES, FL
ZIP 32778-270
Phone: (352) 343-1117
Fax: (866) 445-2968

The NPI 1356332506 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

• Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) (HCPCS:Q0138)
• Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram (HCPCS:Q5101)
• Injection, pembrolizumab, 1 mg (HCPCS:J9271)
• Injection, paclitaxel, 1 mg (HCPCS:J9267)
• Injection, aprepitant, 1 mg (HCPCS:J0185)
• Injection, denosumab, 1 mg (HCPCS:J0897)
• Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg (HCPCS:J1569)
• Injection, iron sucrose, 1 mg (HCPCS:J1756)
• Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg (HCPCS:Q5118)
• Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
• Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count (HCPCS:85025)
• Insertion of needle into vein for collection of blood sample (HCPCS:36415)
• Injection, epoetin alfa, (for non-esrd use), 1000 units (HCPCS:J0885)
• Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units (HCPCS:Q5106)
• Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg (HCPCS:Q5119)
• Injection, palonosetron hcl, 25 mcg (HCPCS:J2469)
• Established patient office or other outpatient visit, 20-29 minutes (HCPCS:99213)
• Blood test, comprehensive group of blood chemicals (HCPCS:80053)
• Injection, ondansetron hydrochloride, per 1 mg (HCPCS:J2405)
• Injection of drug or substance under skin or into muscle (HCPCS:96372)
• Injection, fulvestrant, 25 mg (HCPCS:J9395)
• Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
• Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
• Injection of additional new drug or substance into vein (HCPCS:96375)
• Lactate dehydrogenase (enzyme) level (HCPCS:83615)
• Injection, carboplatin, 50 mg (HCPCS:J9045)
• Gammaglobulin (immune system protein) measurement (HCPCS:82784)
• Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a (HCPCS:G9678)
• Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg (HCPCS:J3420)
• Carcinoembryonic antigen (cea) protein level (HCPCS:82378)
• Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
• Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less (HCPCS:96367)
• Ferritin (blood protein) level (HCPCS:82728)
• Iron level (HCPCS:83540)
• Injection, fluorouracil, 500 mg (HCPCS:J9190)
• Injection, diphenhydramine hcl, up to 50 mg (HCPCS:J1200)
• Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg (HCPCS:J9201)
• Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 (HCPCS:86300)
• Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
• Iron binding capacity (HCPCS:83550)
• Administration of additional new drug or substance into vein, 1 hour or less (HCPCS:96417)
• Infusion into a vein for therapy, prevention, or diagnosis, each additional hour (HCPCS:96366)
• Cyanocobalamin (vitamin b-12) level (HCPCS:82607)
• Injection, zoledronic acid, 1 mg (HCPCS:J3489)
• Measurement of immunoglobulin light chains (HCPCS:83521)
• Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96402)
• Transferrin (iron binding protein) level (HCPCS:84466)
• Infusion into a vein for hydration, each additional hour (HCPCS:96361)
• Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96401)
• Injection of drug or substance into vein (HCPCS:96374)
• Blood test, clotting time (HCPCS:85610)
• Blood test, thyroid stimulating hormone (tsh) (HCPCS:84443)
• Magnesium level (HCPCS:83735)
• Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional (HCPCS:99211)
• Automated urinalysis test (HCPCS:81003)
• Leuprolide acetate (for depot suspension), 7.5 mg (HCPCS:J9217)
• Protein measurement, serum (HCPCS:84165)
• Immunologic analysis technique on serum (immunofixation) (HCPCS:86334)
• Initial hospital inpatient care per day, typically 50 minutes (HCPCS:99222)
• Injection, methylprednisolone sodium succinate, up to 40 mg (HCPCS:J2920)
• Psa (prostate specific antigen) measurement, total (HCPCS:84153)
• New patient office or other outpatient visit, 45-59 minutes (HCPCS:99204)
• Administration of additional new drug or substance into vein using push technique (HCPCS:96411)
• Follow-up hospital inpatient care per day, typically 15 minutes (HCPCS:99231)
• Infusion, normal saline solution , 1000 cc (HCPCS:J7030)
• Injection, magnesium sulfate, per 500 mg (HCPCS:J3475)
• Beta-2 microglobulin (protein) level (HCPCS:82232)
• Follow-up hospital inpatient care per day, typically 25 minutes (HCPCS:99232)
• Folic acid level, serum (HCPCS:82746)
• Infusion, normal saline solution, sterile (500 ml = 1 unit) (HCPCS:J7040)
• Immunologic analysis for detection of tumor antigen, quantitative; ca 125 (HCPCS:86304)
• Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l (HCPCS:G0498)
• Uric acid level, blood (HCPCS:84550)
• Injection, methylprednisolone sodium succinate, up to 125 mg (HCPCS:J2930)
• Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion (HCPCS:96368)
• Erythropoietin (protein) level (HCPCS:82668)
• New patient office or other outpatient visit, 60-74 minutes (HCPCS:99205)
• Testosterone (hormone) level, total (HCPCS:84403)
• Phosphate level (HCPCS:84100)
• Established patient office or other outpatient visit, 10-19 minutes (HCPCS:99212)
• Thyroxine (thyroid chemical), free (HCPCS:84439)
• Urinalysis, manual test (HCPCS:81002)
• Initial hospital inpatient care per day, typically 70 minutes (HCPCS:99223)
• Blood test, basic group of blood chemicals (calcium, total) (HCPCS:80048)
• Thyroid hormone, t3 measurement, free (HCPCS:84481)
• Infusion into a vein for hydration, 31-60 minutes (HCPCS:96360)
• Red blood count, manual test (HCPCS:85044)
• Administration of chemotherapy into vein using push technique (HCPCS:96409)
• Red blood count, automated test (HCPCS:85045)
• Vitamin d-3 level (HCPCS:82306)
• Biopsy and aspiration of bone marrow sample for diagnosis (HCPCS:38222)
• New patient office or other outpatient visit, 30-44 minutes (HCPCS:99203)
• Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromise (HCPCS:M0220)
• Measure of severe acute respiratory syndrome coronavirus 2 (covid-19) antibody (HCPCS:86769)
• Immunologic analysis for detection of tumor antigen, quantitative; ca 19-9 (HCPCS:86301)
• Blood test, lipids (cholesterol and triglycerides) (HCPCS:80061)
• Haptoglobin (serum protein) level (HCPCS:83010)
• Hemoglobin a1c level (HCPCS:83036)
• Established patient office or other outpatient visit, 40-54 minutes (HCPCS:99215)
• Initial hospital inpatient care per day, typically 30 minutes (HCPCS:99221)
• Hepatitis b core antibody measurement (HCPCS:86704)

The enumeration date for this NPI number is 11/4/2005 and was last updated on 8/8/2022.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available:

Other Identifiers

The following information regarding additional identifiers associated to this NPI record includes the other identifier number, identifier type, identifier state and issuer.